Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED BALANCE SHEETS

v2.4.0.8
CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)
Sep. 30, 2014
Dec. 31, 2013
Current assets    
Cash $ 619   
Total current assets 619   
Fixed assets - net 648 1,230
Total Assets 1,267 1,230
Current liabilities    
Accounts payable 639,171 421,597
Accrued interest payable 368,094 268,950
Notes payable - current -non related parties 573,516 573,516
Notes payable - current, net 654,023 612,342
Derivative liability 72,456 150,067
Stock subscription payable - current 28,067 26,000
Related party payables 280,765 190,765
Other payables 241,225 238,085
Total current liabilities 2,857,317 2,481,322
Notes payable - non related parties 167,007 167,007
Total Liabilities 3,024,324 2,648,329
Stockholders' Deficit    
Common stock, $.00001 par value; 100,000,000 shares authorized; 42,903,319 and 34,146,712 shares issued and outstanding at September 30, 2014 and December 31, 2013 respectively 430 342
Additional paid in capital 12,582,399 12,415,639
Deficit accumulated during the development stage (15,572,078) (15,032,660)
Total Transbiotec, Inc. stockholders' deficit (2,989,249) (2,616,679)
Noncontrolling interest (33,808) (30,420)
Total Stockholders' Deficit (3,023,057) (2,647,099)
Total Liabilities and Stockholders' Deficit $ 1,267 $ 1,230